Human cytomegalovirus contains an envelope glycoprotein of 58 kilodaltons (gp58). The protein, which is derived from a glycosylated precursor molecule of 160 kilodaltons via proteolytic cleavage, is capable of inducing neutralizing antibodies. We have mapped the epitopes recognized by the neutralizing monoclonal antibody 7-17 and a second antibody (20, 41) . The most immunogenic polypeptides are phosphoproteins of 150, 65, and 28 kilodaltons (kDa) (20) . These proteins, however, do not induce neutralizing antibodies. Only three polypeptides which are recognized by neutralizing monoclonal antibodies or monospecific sera have been identified; these are glycoproteins of 86 (9, 35), 65 (5), and 58 kDa (4, 33). More recently, a fourth glycoprotein of an estimated 47 to 52 kDa has been described (15). Of these proteins, gp58 has been characterized in the most detail (2, 4, 6, 12, 21, 30, 31, 33, 34) . Within the envelope of the virus, gp58 is complexed by disulfide bonding with another protein which is highly heterogeneous in size, ranging from 95 to 130 kDa (4, 30). The 95-to 130-kDa polypeptide is antigenically unrelated to gp58 but has been shown to be structurally related to a large polyprotein precursor of gp58 (6, 21) . gp58 and the diffusely migrating glycoprotein of Mr 95,000 to 130,000 are thought to be derived from a glycosylated precursor molecule of 160 kDa via proteolytic cleavage (6), with gp58 representing the carboxy-terminal portion of the processed polypeptide (24). The genomic location of the sequence encoding gp58 was identified within the HindIII F fragment of HCMV AD169 by using a procaryotic cDNA expression library and a monospecific rabbit antiserum (24 (31) . Interestingly, the translation product of the gpS8 reading frame shows homology to glycoproteins of the other human herpesviruses, namely, gpII of varicella-zoster virus (M. Mach, unpublished results), gB of herpes simplex virus, and the BALF4 reading frame product of Epstein-Barr virus (8), which has recently been shown to be a 125-kDa glycoprotein (11). The high degree of conservation which is also demonstrated by crossreaction of antisera (1) seems to imply that these glycoproteins play an important role in the infectivity of the respective viruses. This role for gB of herpes simplex virus and gpII of varicella-zoster virus has been clearly shown (17, 22) 
I-galactosidase fusion proteins. The reactivities of antibodies 7-17 and 27-287 were determined by Western blot (immunoblot) analysis. Both antibodies recognized sequences between amino acids 608 and 625 of the primary gp58 translation product. The antibodies almost completely inhibited one another in a competitive binding assay with intact virus as antigen. Moreover, antibody 27-287 was able to inhibit the complement-independent neutralizing activity of antibody 7-17. Human cytomegalovirus (HCMV) has been shown to be an important pathogen in humans. Immunocompromised individuals including organ allograft recipients, patients with acquired immunodeficiency syndrome, and human fetuses develop severe and not infrequently fatal HCMV infections (25, 28, 39) . At present, no highly effective chemotherapy or widely utilized vaccine is available. A major obstacle in developing effective tools to curb the consequences of HCMV infections is the limited knowledge about the molecular biology of the virus and about the antigenic structures involved in the immune response.
The viral particle contains 35 to 45 structural proteins, most of which are capable of inducing an antibody response (20, 41) . The most immunogenic polypeptides are phosphoproteins of 150, 65, and 28 kilodaltons (kDa) (20) . These proteins, however, do not induce neutralizing antibodies. Only three polypeptides which are recognized by neutralizing monoclonal antibodies or monospecific sera have been identified; these are glycoproteins of 86 (9, 35) , 65 (5) , and 58 kDa (4, 33) . More recently, a fourth glycoprotein of an estimated 47 to 52 kDa has been described (15) . Of these proteins, gp58 has been characterized in the most detail (2, 4, 6, 12, 21, 30, 31, 33, 34) . Within the envelope of the virus, gp58 is complexed by disulfide bonding with another protein which is highly heterogeneous in size, ranging from 95 to 130 kDa (4, 30) . The 95-to 130-kDa polypeptide is antigenically unrelated to gp58 but has been shown to be structurally related to a large polyprotein precursor of gp58 (6, 21) . gp58 and the diffusely migrating glycoprotein of Mr 95,000 to 130,000 are thought to be derived from a glycosylated precursor molecule of 160 kDa via proteolytic cleavage (6) , with gp58 representing the carboxy-terminal portion of the processed polypeptide (24) . The genomic location of the sequence encoding gp58 was identified within the HindIII F fragment of HCMV AD169 by using a procaryotic cDNA expression library and a monospecific rabbit antiserum (24 (31) . Interestingly, the translation product of the gpS8 reading frame shows homology to glycoproteins of the other human herpesviruses, namely, gpII of varicella-zoster virus (M. Mach, unpublished results), gB of herpes simplex virus, and the BALF4 reading frame product of Epstein-Barr virus (8) , which has recently been shown to be a 125-kDa glycoprotein (11) . The high degree of conservation which is also demonstrated by crossreaction of antisera (1) seems to imply that these glycoproteins play an important role in the infectivity of the respective viruses. This role for gB of herpes simplex virus and gpII of varicella-zoster virus has been clearly shown (17, 22) , suggesting a similar function(s) for HCMV gp58.
A more detailed analysis of gp58 is important for several reasons, the most obvious being the development of a subunit vaccine. At present, only live, attenuated virus strains are available as immunogens (32) . The expression plasmids, except for pUU5816e, were constructed in the pEX vector system, which allows insertion of DNA fragments in all three reading frames (40) . pUU5816e contains a 1.3-kilobase EcoRI-BamHI fragment in a pUR vector (37) .
Induction of fusion proteins. Fusion proteins were produced in Escherichia coli strain pop2136. The cells were grown to a density of 0.2 to 0.3 (A6.) at 30°C and induced by a quick temperature shift to 42°C. Synthesis of the fusion protein was allowed to continue for 90 min. Then the cells were harvested by centrifugation, lysed in sodium dodecyl sulfate-gel sample buffer and analyzed on 8% acrylamide gels as described elsewhere (19) .
Protein gel electrophoresis and Western blot (immunoblot) analysis. Polypeptides were analyzed on polyacrylamide gels essentially as described previously (4, 24) . For Western blot analysis, proteins were transferred to nitrocellulose membranes as described previously (5) . Binding of antisera or monoclonal antibodies was detected by 125I-protein A as described previously (5) .
In vitro mutagenesis. Plasmid pUU5813 was digested with BglII, and the recessed termini were filled in with Klenow polymerase. KpnI linker molecules (5'-GGGTACCC-3') were ligated, and the DNA was transfected into E. coli pop2136. DNA from recombinant clones was digested with KpnI, and excessive linker molecules were removed by separation on agarose gels. The DNA was religated and transfected again into E. coli. Recombinant clones were isolated, and the insertion of the linker molecule was confirmed by a KpnI digest of the resulting plasmid. Multiple insertions of linker molecules were excluded by digestion with SmaI. The nucleotide sequences at the mutated site was determined by the chain termination method with the Pharmacia T7 sequencing kit (38) . A 17-base-pair oligonucleotide (5'-ACTGGGCGAGGACACCG-3') which binds 54 base pairs upstream was used as a primer.
Competitive antibody binding and neutralization assays. Competitive binding assays were carried out by using a modification of a virus-binding assay in which gradientpurified, intact virions were used as an antigen source (4). Briefly, flexible microdilution plates were coated with virions overnight at 4°C. After blocking the plates with Trisbuffered saline (0.05 M Tris plus 0.15 M NaCl, pH 7.5) containing 2% gelatin, the inhibitor antibody was added at an approximate concentration of 1 ,ug/ml and incubated at 37°C for 45 min. After extensive washing, 125I-labeled indicator antibody was added and incubated for 30 min. Results are expressed as percent inhibition of binding of the labeled antibody.
Neutralization kinetics were determined by a modification of a previously published method (42) . A known quantity of input virus (-400 PFU) was incubated with a single monoclonal antibody (1 to 3 ,ug/ml) or with competing antibodies at equal concentrations. Samples were removed at various times and inoculated on indicator human fibroblast monolayers. The surviving virus was calculated by dividing the number of PFU at indicated times by the infectivity of duplicate cultures containing only medium. All incubations were done in the absence of exogenous complement.
RESULTS
Expression of fragments of gp58 and recognition by various monoclonal antibodies. Since the gp58 molecule has not been characterized extensively on the protein level, two assumptions were made before regions of the molecule were expressed. First, although the transmembrane portion of the molecule has not been analyzed experimentally, a computer analysis revealed two hydrophobic domains (amino acids [aa] 711 to 748 and 752 to 772) which fit the criteria for a transmembrane region of an envelope glycoprotein. Whether these potential transmembrane sequences are arranged in a similar fashion as has been proposed for gB of herpes simplex virus, of which three transmembrane-spanning segments have been found (7), is not known. Second, the exact site at which gpS8 is cleaved from the gB precursor molecule has not been determined. Digestion (Fig. 1 ).
All constructs were made in a vector system in which the HCMV DNA was ligated into the 3' termini of the lacZ gene. Expression of the gene(s) resulted in the synthesis of fusion proteins containing HCMV sequences in addition to ,-galactosidase. The gp58-coding sequence was covered in two overlapping constructs. Plasmid pUU5813e contains a 900-base-pair fragment coding for aa 484 to 783, thus covering most of the portion of the protein and the entire transmembrane region. The fusion protein was stably expressed in E. coli and could be readily detected in Coomassie-stained polyacrylamide gels as a polypeptide of 150 kDa ( Fig. 2A) .
Plasmid pUU5816e contained sequences between aa 685 and the end of the molecule. This hybrid protein was unstable. In addition to the full-size product of approximately 145 kDa, a polypeptide of 118 to 120 kDa accumulated in large quantities after the induction of the gene ( Fig. 2A) . In Western blot analyses, the fusion proteins from both constructs were recognized by a monospecific rabbit antiserum raised against viral gp58 (24) . This indicates that the inserted DNA sequences are in the correct reading frame and orientation (Fig. 2B ).
The reactivities of various monoclonal antibodies specific for gpS8 were analyzed in Western blots. Antibodies 7-17, 27-160, 27-287, and 27-180 reacted with pUU5813e but not with pUU5816e. In control experiments, all monoclonal antibodies specifically recognized viral gpS8 (4, 6) . However, in this panel of antibodies only 7-17 exhibited neutralizing activity, raising the possibility that we could use these procaryotic constructs to identify the neutralizing epitope recognized by antibody 7-17. To determine the binding site precisely, various overlapping subclones of pUU5813e were constructed and tested for reactivity with antibodies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and 27-287.
Mapping of the epitope recognized by antibodies 7-17 and 27-287. Four subclones of the 900-base-pair PstI region were constructed (Fig. 1 Figure 2A shows a comparison of protein extracts from pUU5813e and the mutagenized plasmid pUU5813e*. Both clones synthesized a fusion protein of equal size, indicating that an in-frame insertion had in fact occurred. In Western blots the respective fusion proteins were recognized by the iS P-galactosidase monospecific anti-gp58 serum (data not shown). The DNA nonospecific gp58 sequence of pUU5813e* revealed the insertion of the amino )lasmlids were el-acids Met-Gly-Tyr-Pro (data not shown). In Western blots, ooasysiaebrillianet monoclonal antibodies 7-17 ( Fig. 4A ) and 27-287 (Fig. 4B) nes (B Immunoblot analysis of the neutralizing epitope of gp58. Bacteria containing plasmids pUU5813e, pUU170e, p132e, p135e, and pEX-3 were induced, subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and transferred to nitrocellulose membranes. Duplicate membranes were probed with monoclonal antibodies 7-17 (A) and 27-287 (B). Antibody binding was detected by rabbit anti-mouse immunoglobulin G followed by 1251-protein A and autoradiography. (Fig. 3) , both antibodies strongly recognized the fusion protein pUU5813, whereas protein extracts from the vector (pEX) and fusion proteins from a plasmid expressing carboxy-terminal sequences of gp58 (pUU5816e) did not react. This provides additional proof that the amino acid sequence surrounding the BglII site is critical for the binding of the neutralizing antibody [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Surprisingly, the binding of the nonneutralizing antibody 27-287 was also dependent on the integrity of the BglII site at nucleotide 1847, suggesting close proximity of the epitopes recognized by these antibodies (Fig. 4B) .
Antibody 27-287 competitively inhibits antibody 7-17 gp58- FIG. 4 . Identification of the neutralizing epitope of gp58. Bacteria containing the plasmids pUU5813e, pUU5813e*, pUU5816, and pEX were analyzed as described in the legend to Fig. 3 7-17  96  92  0  27-287  83  87  5  27-39  25  22  20  14-9 18 NT 100 a 7-17, 27-287, and 27-39 are anti-gp58, and 14-9 is anti-gp65. Wells coated with 0.1 ,ug of gradient-purified virus were preincubated with approximately 1 Fg of antibody per ml for 45 min and washed extensively before addition of labeled antibody.
b Percent inhibition of binding in the presence of diluent only. Purified monoclonal antibody was radiolabeled with 1251 (specific activity, 1 to 10 p.Ci/pg), and approximately 200,000 cpm was added to virus-coated wells preincubated with unlabeled inhibitor antibody. After a 30-min incubation, the wells were extensively washed and bound radioactivity was determined.
( Table 1) . Thus, in agreement with results presented in the section above, it appeared that both antibody 27-287 and 7-17 reacted with either the same or proximally located epitopes.
We then investigated the interaction between these antibodies in the complement-independent neutralization of HCMV. As was reported previously (4), antibody 7-17 neutralized HCMV whereas antibody 27-287 failed to cause A 60 a significant reduction in infectivity (Fig. 5) . When equal concentrations of antibody 7-17 and 27-287 were incubated together with infectious virus, antibody 27-287 inhibited the neutralizing activity of antibody [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] by nearly 50% (Fig. 5) . This effect on the neutralizing activity of antibody 7-17 was specific, since addition of antibody 27-287 failed to inhibit the neutralizing activity of a second, unrelated anti-gp58 antibody, 27-39 (Fig. 5) . Because of the apparent proximity of the epitopes recognized by antibodies 7-17 and 27-287, these results suggest that antibodies generated in vivo after HCMV infection may also interact to reduce the overall neutralizing response. Future experiments will examine the relevance of this finding.
DISCUSSION
Glycoprotein gp58 of HCMV is clearly immunogenic, since previous studies have shown that both recombinant derived gp58 and affinity-purified protein can induce neutralizing antibodies (8, 34) . In addition, because of its abundance and its homology to major glycoproteins of other herpesviruses, this protein probably plays an essential role in the life cycle of HCMV. A detailed description of the immunoreactive sequences of gp58, particularly those involved in recognition by virus-neutralizing antibodies, would be of extreme value in designing potential subunit vaccines to protect against severe HCMV disease.
We (26, 36) and recently, an extensive study of conformational epitopes present on HCMV gp58 (gC-1) has been published (23) . This study also noted the competitive inhibition of several monoclonal antibodies directed against related domains of gp58 (23) 
